Novolog Pharm Up 1966 Stock Total Asset
| NVLG Stock | 169.70 2.90 1.68% |
Novolog Pharm Up 1966 fundamentals help investors to digest information that contributes to Novolog Pharm's financial success or failures. It also enables traders to predict the movement of Novolog Stock. The fundamental analysis module provides a way to measure Novolog Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novolog Pharm stock.
Novolog |
Novolog Pharm Up 1966 Company Total Asset Analysis
Novolog Pharm's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Novolog Pharm Total Asset | 2.29 B |
Most of Novolog Pharm's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novolog Pharm Up 1966 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Novolog Pharm Up 1966 has a Total Asset of 2.29 B. This is 69.57% lower than that of the Health Care Providers & Services sector and 57.13% lower than that of the Health Care industry. The total asset for all Israel stocks is 92.23% higher than that of the company.
Novolog Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novolog Pharm's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novolog Pharm could also be used in its relative valuation, which is a method of valuing Novolog Pharm by comparing valuation metrics of similar companies.Novolog Pharm is currently under evaluation in total asset category among its peers.
Novolog Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0174 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 508.7 M | |||
| Shares Owned By Insiders | 42.45 % | |||
| Shares Owned By Institutions | 40.71 % | |||
| Price To Book | 3.24 X | |||
| Price To Sales | 0.99 X | |||
| Revenue | 1.26 B | |||
| Gross Profit | 154.67 M | |||
| EBITDA | 115.92 M | |||
| Net Income | 42.32 M | |||
| Cash And Equivalents | 107.97 M | |||
| Cash Per Share | 0.31 X | |||
| Total Debt | 916 K | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 0.86 X | |||
| Cash Flow From Operations | 83.39 M | |||
| Earnings Per Share | 0.08 X | |||
| Target Price | 2.1 | |||
| Number Of Employees | 900 | |||
| Beta | 0.2 | |||
| Market Capitalization | 1.09 B | |||
| Total Asset | 2.29 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 2.29 B | |||
| Last Dividend Paid | 0.063 |
About Novolog Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novolog Pharm Up 1966's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novolog Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novolog Pharm Up 1966 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Novolog Stock
Novolog Pharm financial ratios help investors to determine whether Novolog Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novolog with respect to the benefits of owning Novolog Pharm security.